We are pleased to be recommended again in the latest…
H. Ulrich Dörries
Partner
Dr. sc. nat., Dipl.-Biol.
Dr. Dörries has been active in intellectual property since 1993 and is co-founder and partner of df-mp. His technical expertise inter alia spans the areas molecular biology, biotechnology, immunology, pharmaceuticals and polymer chemistry. His legal qualifications enable him to represent clients before the German Patent and Trademark Office (GPTO), the European Patent Office (EPO), the German Federal Patent Court (GFPC), the German Federal Supreme Court (FSC; in appeals from the GFPC), the Unified Patent Court (UPC) and the European Union Intellectual Property Office (EUIPO).
+ 49 89 210 296 0
ulrich.doerries@df-mp.com
Dr. Dörries has been active in intellectual property since 1993 and is co-founder and partner of df-mp. His technical expertise inter alia spans the areas molecular biology, biotechnology, immunology, pharmaceuticals and polymer chemistry. His legal qualifications enable him to represent clients before the German Patent and Trademark Office (GPTO), the European Patent Office (EPO), the German Federal Patent Court (GFPC), the German Federal Supreme Court (FSC; in appeals from the GFPC), the Unified Patent Court (UPC) and the European Union Intellectual Property Office (EUIPO).
practice areas.
A main aspect of Dr. Dörries’ practice is advising and representing clients in opposition proceedings, nullity actions and patent infringement proceedings and providing corresponding opinions. He has successfully enforced and/or defended his clients’ interests in various high profile patent disputes. Another aspect of his practice is drafting and prosecuting patent applications before the GPTO and the EPO. He has furthermore comprehensive expertise in advising on supplementary protection certificates and coordinating the filing and prosecution of corresponding applications in Germany and throughout Europe.
We are delighted to be listed again in this year's…
df-mp is one of three German patent and trademark law…
df-mp joins the ranks of "highly recommended" patent law firms…
We proudly announce that df-mp is among the most recommended patent…
Teva and df-mp can report another success: In an appeal…
Sucess for Ceva: The company is now allowed to market its…
df-mp is proud to receive another five IP stars this…
The pharmaceutical companies Hexal and Teva may continue to sell…
df-mp is delighted that five partners have been awarded the…
admissions.
- German Patent Attorney
- European Patent Attorney
- European Trademark Attorney
- European Design Attorney
references and activities.
- Authored various scientific articles in international journals
- Authored various articles on the development of patent law in the field of biotechnology/pharmaceuticals
- Speaker at various international patent conferences (organized, e.g., by EuroForum, EuroLegal, IQPC, ACI, CIPA – Chartered Institute of Patent Agents, EPLA, C5 etc.) on topics related to the procurement and enforcement of IP rights in the pharmaceutical/biotech area
- Recommended in IAM 1000 2018 for “Prosecution and Nullity” in Germany
- Named as IP Star in the “Managing Intellectual Property (MIP) Handbook” 2018
- Listed as “Most Highly Regarded” in the category “Patent Agents” in Who’s Who Legal: Germany 2019
curriculum vitae.
Since 2000
Co-founder and partner at df-mp
1993-2000
Associate at the law firm of Bardehle Pagenberg and subsequently at the Frohwitter law firm, both in Munich.
1993
Doctorate Degree in Molecular Biology (with a specialty in neurobiology) from the Swiss Federal Institute of Technology in Zurich, Switzerland.
1989
Diploma in Biology from the Ruprecht-Karls-University in Heidelberg (diploma thesis in the area of gene regulation via transcription factors).
Representative cases.
- Escitalopram / Cipralex®: nullity action (Federal Supreme Court (FSC) Xa ZR 130/07 – Escitalopram
- Memantin / Memantin Merz®: nullity action (FSC X ZR 68/08 – Memantine)
- Factor VIII / Octanat®: nullity action, FSC X ZR 77/12 – Protein Separation
- Quetiapin / Seroquel XR®: nullity action, FSC X ZR 41/13 – Quetiapine
- Valganciclovir / Valcyte®: nullity action, BGH X ZR 105/14 – Valganciclovir
- Pregabalin / Lyrica®: patent infringement proceedings
- Erlotinib / Tarceva®: nullity action
- DMF / Tecfidera®: opposition proceedings, utility model cancellation proceedings, patent infringement proceedings
- Tadalafil / Cialis®: nullity action
- Pirfenidon / Esbriet®: opposition proceedings
- Tenofovir-Emtricitabin / Truvada®: nullity action re. SPC
- Denosumab / Prolia®, Xgeva®: various opposition proceedings
- Natalizumab / Tysabri®: nullity action
- Evolocumab / Repatha®/ Alirocumab®/ Praluent®: opposition proceedings, patent infringement proceedings, compulsory license proceedings
association memberships.
